Evidence map›Paper›PMID 41420827›Full record

ArticleJournal of clinical apheresis2025

Poor Mobilization and Plerixafor Use in Matched Related Peripheral Hematopoietic Progenitor Cell Donors.

Elizabeth A Godbey, Nicole L Draper, Laura Connelly-Smith, Caroline Alquist, Joseph Schwartz, Leonor Fernando, Andrew Jones, Amy E Schmidt, Charles Harmon, Esther Lee and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical apheresis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Elizabeth A GodbeyDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, Florida, USA.
Nicole L DraperDepartment of Pathology, University of Colorado Anschutz Medical Campus, Denver, Colorado, USA.
Laura Connelly-SmithFred Hutch Cancer Center, Seattle, Washington, USA.
Caroline AlquistHoxworth Blood Center, University of Cincinnati, Cincinnati, Ohio, USA.
Joseph SchwartzFoundation for the Accreditation of Cellular Therapy (FACT), Omaha, Nebraska, USA.
Leonor FernandoDepartment of Pathology and Laboratory Medicine, University of California Davis, Sacramento, California, USA.
Andrew JonesDepartment of Laboratory Medicine, UCSF Benioff Children's Hospital Oakland, Oakland, California, USA.
Amy E SchmidtHCA, Denver, Colorado, USA.
Charles HarmonHelena Laboratory Physicians/St. Peter's Health, Helena, Montana, USA.
Esther LeeUniversity of Michigan Medical School, University of Michigan, Ann Arbor, Michigan, USA.
Yevgeniy LinnikDepartment of Medical Affairs, Labcorp Biopharma, Indianapolis, Indiana, USA.
Laura CoolingDepartment of Pathology, University of Michigan, Ann Arbor, Michigan, USA.ORCID https://orcid.org/0000-0003-0216-1599

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Plerixafor (PLX) is FDA approved for use in autologous peripheral blood stem cell donors but not in allogeneic donors. This study was completed by members of the ASFA HPC Donor Subcommittee to examine the incidence and characteristics of poor mobilizers (PM) among matched related donors (MRD), as well as factors associated with PLX use in MRD. Risks of poor mobilization in MRD were older age, especially donors older than 60 years, lower baseline platelet counts, and heavier recipients. PLX use in PM was low but safe, tripling the success rate for collection. This study adds evidence to the body of literature to support use of PLX in allogeneic donors who are PM.

Indexed as

Hematopoietic Stem Cell MobilizationHeterocyclic CompoundsPeripheral Blood Stem CellsAdultAgedBenzylaminesCyclamsFemaleHumansMaleMiddle AgedTissue DonorsBenzylaminesCyclamsHeterocyclic Compoundsplerixaforallogeneic hematopoietic donormatched related donorplerixafor

Identifiers

PMID41420827
PMCPMC12717964

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.